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It is known that thyroid hormones influence a wide variety of events at the molecular, cellular, and functional levels. Thyroid
hormones (TH) play pivotal roles in growth, cell proliferation, differentiation, apoptosis, development, and metabolic homeostasis
via thyroid hormone receptors (TRs) by controlling the expression of TR target genes.Most of these effects result in pathological and
physiological events and are alreadywell described in the literature. Even so,many recent studies have been devoted to bringing new
information on problems in controlling the synthesis and release of these hormones and to elucidating mechanisms of the action
of these hormones unconventionally. The purinergic system was recently linked to thyroid diseases, including enzymes, receptors,
and enzyme products related to neurotransmitter release, nociception, behavior, and other vascular systems.Thus, throughout this
text we intend to relate the relationship between the TH in physiological and pathological situations with the purinergic signaling.
1. An Overview about Thyroid Hormones
Thyroxine (T4), triiodothyronine (T3), and reverse triiodo-
thyronine (rT3) are the three main forms of thyroid hor-
mones (TH) found in the bloodstream. T4 and T3 are essen-
tial for normal functioning of different systems. TH play
a central role in the growth, proliferation, differentiation,
apoptosis, development, neurotransmission, behavior, and
metabolic homeostasis [1–3].
Themost common effects of TH are those onmetabolism.
TH affect the intermediary metabolism of proteins, lipids,
and carbohydrates in almost all tissues. T3 target genes were
studied by microarray assay in cell lines of hepatocellular
carcinoma and detoxification; cell adhesion, signal trans-
duction, cell migration, transcription factors and cell cycle
oncogenesis were recognized to be regulated by treatment
with T3 [4].
T3 is also able to induce vasodilatation through mech-
anisms not yet fully elucidated [5]. The positive inotropic,
dromotropic, and chronotropic heart rate are also increased
by TH [6]. These effects are associated with an increase in
sensitivity of adrenergic and cardiac receptors, as well as,
an increased synthesis of myosin [7, 8]. Thus, hyperthy-
roidism is common to observe responses such as tachycardia
and cardiac hypertrophy [6].
In the nervous system, the TH act mainly on the
mechanisms involved in the central and peripheral neuro-
transmission by increasing the synthesis and sensitivity to
catecholamines [9]. Studies have shown a reduction in the
release of glutamate and NMDA receptor expression in rat
brain following the induction of hypothyroidism surgery
[10, 11].The precise mechanism by which the hypothyroidism
induces neurological problems such as memory impairment
is not yet fully elucidated. However, cognitive disturbances
described in patients with untreated hypothyroidism are
often associated with decreased excitability in the central
nervous system (CNS) [12].
In the early stages of brain development in mammals, TH
promote cell proliferation and subsequently act by inhibiting
proliferation and stimulating cell differentiation [13].The lack
of TH during the period of neurogenesis (up to six months of
postnatal life) results in irreversible neurological deficits and
is accompanied by multiple morphological brain alterations
[14]. TH deficiency during the fetal and neonatal periods
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results in disturbances in the process of neuronal migration,
reduction of synaptogenesis, defective myelination, and the
synthesis of neurotransmitters [13–15].
Although the secretion of T4 from thyroid is several times
greater than T3, the later is roughly two to three times more
effective than the former.
Since 1970, most studies have mainly described the con-
cept of genomic action of TH through the transcriptional
regulation of genes responsive to these hormones [16, 17].
T3 binds to specific high affinity receptors called thyroid
receptors (TRs) which belong to the super family of nuclear
receptors and mediate multiple effects on the phenotype,
proliferation, and gene expression of cultured normal mam-
mary epithelial cells [18, 19]. TRs bind to DNA at specific
sequences and the TR response element (TREs) in target gene
promoters.
In addition to nuclear effects mediated by these receptors,
nongenomic actions of TH have been recently characterized
[20, 21]. These activities include effects on the rapid plasma
membrane [22] and cytoplasmic organelles [20]. Many of the
rapid effects mediated by these hormones are not changed
by the use of inhibitors of transcription and translation [21].
Moreover, it is widely demonstrated that membrane-initiated
rapid responses to TH include alterations in ionic fluxes and
in membrane potentials [23, 24]. Some authors also discuss
the possible presence of isoforms of nuclear receptors on the
plasma membrane [25]. It also appears that regulation of the
actin cytoskeleton by T4 facilitates the interaction of trans-
membrane integrins with laminin, the principal extracellular
matrix (ECM) protein in developing brain and a product of
glial cells. This nongenomic action of TH on ECM could
influence relationships of nerve cells during brain develop-
ment [21]. TH are also able to modulate in vivo and in vitro
the vimentin phosphorylation and expression in rat testis
and cerebral cortex through genomic [26] and nongenomic
mechanisms. In this context, the authors of [27] have demon-
strated that T3 provoked vimentin hyperphosphorylation
and association/aggregation into the cytoskeletal fraction of
rat testicular cells. This effect was totally independent on
protein synthesis, characterizing a nongenomic action for this
hormone. Moreover, this effect was dependent on intra- and
extracellular Ca2 levels, and vimentin hyperphosphorylation
was prevented by appropriate blockers of Ca2 influx through
L-VDCC (voltage-dependent Ca2+ channel). These findings
suggest that T3 can play important nongenomic roles in the
reorganization of the cytoskeleton, regulating cell physiology
rat testis [26].
Disorders of the thyroid gland are among the most
common endocrine maladies. Hyperthyroidism is character-
ized by nervousness, anxiety, physical hyperactivity, weight
loss, increased perspiration, increase in metabolic routs, and,
in the most severe situations, seizures. Hypothyroidism is
the most prevalent form of thyroid disease and symptoms
may include memory and learning impairment, depression,
psychotic behavior, retarded locomotor ability, somnolence,
progressive intellectual deterioration, and, in extreme cases,
coma.
Recently, TH and the diseases involved were related
to the purinergic system. Our group has demonstrated
the involvement of some key symptoms of thyroid dysfunc-
tion in the purinergic system in different tissues and biologi-
cal samples, as it will be described throughout this review.
2. An Overview about Purinergic System
The signaling components in the purinergic system are ATP,
P2 receptors, adenosine, adenosine receptors, ectonucleoti-
dases, and nucleoside transporters.
Nucleosides and nucleotides play their actions through
activation of specific membrane purinoceptors. There are
two purinergic receptor families named P1 and P2, which
were identified in 1978 [28]. Purinergic receptors were sub-
divided on the basis of pharmacology (e.g., response to
specific agonists) and molecular cloning [29, 30]. Adenosine
is the endogenous agonist of P1 receptors family, which is
composed by four subtypes of G-protein-coupled receptors
named A1, A2A, A2B, and A3 [28]. The P2 receptor family
is composed by P2X and P2Y receptors subtypes. The P2X
receptors are ligand-gated cation channels composed of
homo- or heterotrimeric P2X subunits, and the P2Y receptors
are seven transmembrane G-protein-coupled receptors [28].
There are seven known P2X receptor subtypes (P2X1–7) and
eight P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11,
P2Y12, P2Y13, and P2Y14) [31].
Adenosine is involved in various physiological and patho-
logical processes, both in the periphery and in the CNS
[32, 33].
The inhibitory actions of adenosine on neurotransmitter
release are mediated by specific plasma membrane A1 recep-
tors [34, 35].The A1 adenosine receptor is the most prevalent
adenosine receptor subtype, having both a high level of
expression and a widespread distribution [33]. Actions due
to adenosine A1 receptors activation have been proposed to
result from coupling to inhibitory protein Gi, inhibition of
adenylate cyclase, inhibition of presynaptic voltage-sensitive
Ca2+ channels, and activation of postsynaptic K+ channels
[36].
Furthermore, adenosine plays a significant role in intra-
cellular signal transduction mechanisms depressing the
release of thyroid-stimulating hormone (TSH) by A1 receptor
activation [37, 38].
The levels of extracellular adenosine are increased during
periods of highmetabolic demand, such as seizures, ischemia,
hypoxia, and stressful challenges [39, 40].
In addition, adenosine-mediated inhibitory influences
on nociceptive reflex responses have been demonstrated in
experimental and clinical situations [41, 42]. It is known that
the antinociceptive properties of adenosine are associated
with adenosine A1 receptor activation at spinal sites [41].
Studies performed in mice lacking the adenosine A1
receptor confirm the involvement of adenosine in motor
activity, exploratory behavior, anxiety, and aggressiveness
[43]. Furthermore, adenosine antagonists like caffeine pro-
mote wakefulness, aggressive behavior in rats, and nervous-
ness and irritability in man [44], while adenosine analogues
counteract these effects [45].
Adenosine is also able to attenuate the deleterious conse-
quences of reactive oxygen species (ROS) through A1 recep-
tors activation in rat hippocampal slices [46]. In addition,
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oxidative stress induces expression of the A1 receptors [47],
which provide cytoprotection in the CNS [48].
ATP is an excitatory synaptic transmitter in both central
and peripheral nervous systems [30, 49]. Extracellular ATP,
at micromolar concentrations, induces significant functional
changes in a wide variety of cells and tissues. It has been
shown that ATP is involved in the interaction between
neurons and glial cells, homeostasis [50], and inflammatory
reactions in the brain [50]. In cultured astrocytes, ATP
induces differentiation, proliferation, and reactive astroglio-
sis in tissue injury [51]. ATP can be released from the cytosol
of damaged cells or from exocytotic vesicles and/or granules
contained in many types of secretory cells. Furthermore,
the cellular ATP level is an important determinant for cell
death. ATP signaling can trigger excitotoxicity via activation
of calcium-permeable P2X7 purinergic receptors. Sustained
activation of P2X7 receptors in vivo causes lesions that
are reminiscent of the major features of demyelination,
oligodendrocyte death, and axonal damage [52].
ATP and adenosine levels are controlled by a sophis-
ticated cascade of cell surface-localized enzymes collectively
known as ectonucleotidases.These enzymes hydrolyze nucle-
oside triphosphates, diphosphates, and monophosphates to
their respective nucleosides. There are five major families
of ectonucleotidases: ectonucleoside triphosphate diphos-
phohydrolases (E-NTPDases), ectonucleotide pyrophospha-
tase/phosphodiesterases (E-NPPs), alkaline phosphatases,
ectonucleoside diphosphokinase (E-NDPK), and ecto-5󸀠-
nucleotidase.
Ectonucleotidases are membrane-bound enzymes with
catalytic site located in the extracellular medium. NTPDase1,
3 and 8 slightly prefer ATP over ADP by a ratio of 1, 3, and
2, respectively, whereas NTPDase 2 prefers triphosphonucle-
osides [53]. Ecto-5󸀠-nucleotidase hydrolyses monophosphate
nucleosides, for example, AMP, and is directly involved in
adenosine production in the synaptic cleft. These enzymes
promote the complete ATP hydrolysis to adenosine and may
play an important role in physiological and pathological
conditions, controlling the activation and the availability of
ligands to nucleotide and nucleoside receptors.
Thus, the effect of the TH on the purinergic system can
influence the actions mediated by the adenine nucleotides
allowing us to understand the features involved in thyroid
dysfunctions.
3. Thyroid Hormones and Purinergic System
It has been previously shown that the sensibility to inhibitory
agents, such as adenosine is increased in the hypothyroid
status [54].
Considering that TH modulate a number of physio-
logical functions in CNS, including development, function,
expression of adenosine A1 receptors, and transport of neu-
romodulator adenosine, we investigated the effects of the
hyperthyroidism and hypothyroidism on the hydrolysis of
the ATP to adenosine in the synaptosomes of hippocampus
and cerebral cortex of rats in different developmental phases
[55, 56]. Hyperthyroidism was induced in male Wistar rats
from different ages by daily injections of l-thyroxine (T4)
for 14 days [55]. Hypothyroidism was induced in these rats
by thyroidectomy and methimazole (0.05%) added to their
drinking water for 14 days. Neonatal hypothyroidism was
induced by adding 0.02% methimazole in the drinking water
from day 9 of gestation and continually until 14 days old
[56]. In these studies, it was possible to observe that hyper-
thyroidism decreased the hydrolysis of ATP to adenosine in
both hippocampus and cerebral cortex synaptosomes, while
hypothyroidism increased the AMP hydrolysis to adenosine
in both hippocampus and cerebral cortex synaptosomes from
rats at all aged tested. These results suggest that the increase
of ATP availability as an excitatory neurotransmitter and the
potential decrease of adenosine as an inhibitory molecule
can be associatedwith some hyperthyroidism symptoms [55].
In contrast, the potential increase in adenosine levels in
brain synaptosomes from hypothyroid rats may explain some
inhibitory effects observed in hypothyroidism [56].
Furthermore, the results observed in synaptosomes were
also seen in hippocampal and cortical slices from hypothy-
roid and hyperthyroid rats [57]. In this study, the increase
in the ATP, ADP, and AMP hydrolysis was reverted by T4
replacement in brain slices from hypothyroid rats. More-
over, hypothyroidism increased the expression of NTPDase1
and 5󸀠-nucleotidase, whereas hyperthyroidism decreased the
expression of this enzyme in hippocampus of adult rats.
Thus, hyperthyroidism and hypothyroidism affect the
extracellular nucleotides balance and adenosine production,
possibly interfering in neurotransmitter release, develop-
ment, and other physiological processes.
In Figure 1, we can observe a representation of the results
describing the effects of hyperthyroidism on the purinergic
system in the CNS.
It has been shown that ATP is involved in the interaction
between neurons and glial cells, homeostasis, and inflamma-
tory reactions in the brain [50]. In cultured astrocytes, ATP
induces differentiation, proliferation, and reactive astroglio-
sis in injured tissue [51]. Therefore, the relation between
the ectonucleotidases and TH was also investigated in brain
cell culture from rats submitted to neonatal hypothyroidism
and demonstrated that the adenine nucleotides hydrolysis
was altered in cerebellar and hippocampal astrocytes from
immature hypothyroid rats. Therefore, the imbalance in
the ATP and adenosine levels in astrocytes during brain
development may contribute to some of the effects described
in neonatal hypothyroidism [60].
Moreover, the effects observed in the nervous system,
were also observed in blood serum of rats at different
developmental stages [55, 56, 59].These results are important
for the possible use of enzyme markers for these thyroid
diseases.
There is increasing evidence that adenosine and ATP
may act as pain neuromodulators in the spinal cord [61, 62].
Adenosine has antinociceptive properties in experimental
and clinical situations [41, 63], while ATP exerts pronoci-
ceptive actions in different pain models [64]. Considering
this relation, our research group investigated the hydrolysis
of ATP to adenosine in synaptosomes from spinal cord in
parallel with the nociceptive response of rats at different



















Figure 1: Schematic figure representing our data relating the purinergic systemwith hyperthyroidism in theCNS.Thefigure demonstrates that
the induction of hyperthyroidism resulted in a significant reduction in the NTPDases and 5󸀠-nucleotidase (5󸀠-NUC) activities which degrade
the ATP to adenosine in the brain rats chronically treated with T4 [55]. This result was also observed in 5󸀠-nucleotidase expression in brain
of hyperthyroid rats [57]. This leads to an increase of ATP availability as an excitatory neurotransmitter and the reduction of adenosine as an
inhibitory neuromodulator in different brain fractions studied. The reduction in the extracellular adenosine levels may reduce the inhibitory
effects mediated by adenosine A1 receptors. This relation was demonstrated in hyperthyroidism, once that N6-cyclopentyladenosine (CPA),
a selective agonist of the A1 adenosine receptor, reverted the hyperalgesia induced by hyperthyroidism and increased the total antioxidant
reactivity in hyperthyroid brain [58].Moreover, the effects observed in the nervous systemwere also observed in blood serum of hyperthyroid
rats, indicating a possible use of soluble enzyme markers for this thyroid disease [55, 59].
ages after hyperthyroidism and hypothyroidism induction
[58, 65]. Hypothyroidism elicited a significant increase in
AMP hydrolysis to adenosine in synaptosomes from spinal
cord in parallel with a pronounced analgesic response. Thus,
a possible increase in the adenosine levels could justify the
analgesic response observed in hypothyroid rats [58]. Simi-
larly, the increase in the nociceptive response in hyperthyroid
rats could be justified by the decrease in the hydrolysis of ATP
to adenosine in the spinal cord from these rats, emphasizing
the relation between ectonucleotidases and nociception in
thyroid diseases [65].
It is known that the protective and inhibitory effects of
adenosine are mediated by A1 receptors. These inhibitory
effects occur in such processes such as neurotransmitter
release, nociception, motor activity, exploratory behavior,
anxiety, and reactive oxygen species (ROS) effects.Therefore,
in a previous study we investigated the consequences of the
administration of a specific agonist of adenosine A1 receptor
on behavioral and biochemical parameters after hyperthy-
roidism induction [58]. In this study, we used a selective
adenosine A1 receptor agonist, N6-cyclopentyladenosine
(CPA), in hyperthyroid rats. The results demonstrated that
CPA reverted the hyperalgesia induced by hyperthyroidism
and decreased the exploratory behavior, locomotion, and
anxiety in hyperthyroid rats. Furthermore, CPA decreased
lipid peroxidation in hippocampus and cerebral cortex of
control rats and in cerebral cortex of hyperthyroid rats. CPA
also increased the total antioxidant reactivity in hippocampus
and cerebral cortex of control and hyperthyroid rats. These
results suggest that some of the hyperthyroidism effects are
subjected to regulation by adenosine A1 receptor, demon-
strating the involvement of the adenosinergic system in this
pathology.
The relation between the TH and the purinergic system
was also demonstrated in testis. Since, the Sertoli cells present
in the seminiferous tubules provide physical support to germ
cells, form the blood testis barrier, and secrete protein prod-
ucts which are thought to be essential for the maintenance
and control of spermatogenesis [66], the hormonal factors
controlling the duration of Sertoli cell proliferation are critical
determinants of fertility [67]. Alterations in thyroid activity
are frequently associated with changes in male reproductive
functions, since hypothyroidism, induced or occurring soon
after birth, is associated with a marked delay in sexual mat-
uration and development [68]. In addition to the hormonal
modulation of Sertoli cell functions, there are several reports
evidencing that extracellular adenine nucleotides can mod-
ulate responses through the purinoceptors present in these
cells [69–73]. In a previous study, the enzymes NTPDase 1, 2,
and 3 were detected by RT-PCR in Sertoli cell cultures [26].
However, hypothyroidismwas not able to alter the expression
of these enzymes, but significantly decreased the extracellular
ATP and ADP hydrolysis. These findings demonstrate that
TH modify NTPDase activities in hypothyroid Sertoli cells,
probably via nongenomic mechanisms and, consequently,
may influence the reproductive function throughout devel-
opment [26].
Furthermore, the maintenance of the normal vascular
function also has been related with the purinergic system
[74]. TH has an inhibitory effect on the platelet aggregation
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in vitro [75] and in vivo [76]. Accordingly, hypothyroid
patients present an increase in platelet aggregation, while
hyperthyroid patients have a decrease in this process. More-
over, hypothyroidism has been associated with diseases such
as artherosclerosis and thrombosis [77, 78]. Depending on
the concentration, ATP can stimulate or inhibit platelet
aggregation [79]. On the other hand, ADP is a potent
platelet-recruiting factor inducing platelet aggregation [29].
We previously demonstrated a significant increase in the
AMP hydrolysis in platelets from hyperthyroid rats and a
decrease of the hydrolysis of this nucleotide in response to
hypothyroidism. Besides, the T4 replacement significantly
reversed the inhibition of the AMP hydrolysis observed in
hypothyroid rats. These findings indicate that the thyroid
disorders affect the 5󸀠-nucleotidase activity and consequently
can alter the adenosine levels in a reversible manner in plate-
let fraction. Since, adenosine is able to inhibit platelet aggre-
gation and acts as a potent vasodilator, these results can
contribute to a better comprehension of the vascular events
described in thyroid disorders [79].
There was undertaking studies to evaluate the role of TH
in the extracellular nucleotide hydrolysis by ecto-NTPDase
in the cardiac cells. A previous study demonstrated that T3
increase the ATP and ADP hydrolysis and the NTPDase 3
messenger RNA levels in primary cultures of rat ventricular
myocytes [80]. Since T3 promotes an increase in the contrac-
tile protein, leading to cardiac hypertrophy, it is tempting to
postulate that the increase inATP hydrolysis and the decrease
in the extracellular levels signify an important factor for
prevention of excessive contractility [80].
It was recently demonstrated that hypothyroidism signif-
icantly increases the 5󸀠-nucleotidase activity in the soluble
fraction of cardiac tissue in a reversible manner. These data
indicates that TH can influence adenosine production and
possibly contribute to the cardioprotective effect and the
maintenance of cardiac function under TH privation [81].
In the cardiac tissue, the intra- and extracellular levels of
adenosine can be regulated through hydrolytic deamination
to inosine by adenosine deaminases (ADA) [82]. In a previous
study, ADA inhibition significantly enhanced the efficiency of
A1 adenosine receptor signaling pathway in the hyperthyroid
guinea pig atrium. This result suggests that elevated intracel-
lular adenosine level caused by ADA inhibition may improve
the suppressed responsiveness to A1 adenosine receptor
agonists associated with the hyperthyroid state [83].
Adenosine also decreases O
2
demand by reducing the
heart rate (a negative chronotropic effect), atrioventricular
conduction (a negative dromotropic effect), and contractile
force (a negative inotropic effect). It increases O
2
supply by
causing coronary vasodilatation [84]. Studies have also
shown that the levels of A1 adenosine receptors in the heart
correspond to heart rate and to cardiac efficiency [85].
Moreover, the ATP receptors, as well as P2X7 receptor,
were also linked with other pathological situation such as
thyroid cancer.The P2X7 receptor was upregulated in thyroid
cancer lines. Thyroid cancer cells had at least a 3-fold higher
intracellular ATP concentration and maintained at least a 3-
fold higher extracellular ATP level, compared with control
cells, suggesting that an enhanced P2X7 receptor function
may be a feature of human thyroid cancer or can be used as
a new potential marker of this disease [86]. Furthermore, the
P2X7 receptor expression was also related to tumor size and
capsular infiltration of papillary thyroid carcinoma, being
described as possible predictors for lymph node metastasis
in this kind of carcinoma [87].
Taken together, the studiesmentioned in this text demon-
strate the strong relationship between TH and the purinergic
signaling in different physiological and pathological systems.
Here, wementioned the association between some symptoms
of thyroid pathologies, with the enzymes responsible for the
maintenance of ATP and adenosine levels, as well as with
the A1 adenosine receptors. This relationship may, in some
way, help us understandmany of the effects observed in these
pathologies.
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[77] C. Erem, H. Kavgaci, H. Ersöz et al., “Blood coagulation and
fibrinolytic activity in hypothyroidism,” International Journal of
Clinical Practice, vol. 57, no. 2, pp. 78–81, 2003.
[78] J. D. Wilson and D. W. Foster, “The thyroid gland,” Endocrinol-
ogy, pp. 682–815, 1985.
8 Journal of Thyroid Research
[79] A. N. Bruno, D. Pochmann, F. K. Ricachenevsky, C. D. Bonan,
M. L. M. Barreto-Chaves, and J. J. F. Sarkis, “5󸀠-nucleotidase
activity is altered by hypo- and hyperthyroidism in platelets
from adult rats,” Platelets, vol. 16, no. 1, pp. 25–30, 2005.
[80] M. L.M. Barreto-Chaves,M. S. Carneiro-Ramos, G. Cotomacci,
M. B. C. Júnior, and J. J. F. Sarkis, “E-NTPDase 3 (ATP diphos-
phohydrolase) from cardiomyocytes, activity and expression
are modulated by thyroid hormone,” Molecular and Cellular
Endocrinology, vol. 251, no. 1-2, pp. 49–55, 2006.
[81] G. Cotomacci, J. J. Sarkis, C. R. Fürstenaua, and M. L. Barreto-
Chaves, “Thyroid hormones are involved in 5’-nucleotidase
modulation in soluble fraction of cardiac tissue,” Life Science,
vol. 91, no. 3-4, pp. 137–142, 2012.
[82] L. Willems, M. E. Reichelt, J. G. Molina et al., “Effects of ade-
nosine deaminase and A
1
receptor deficiency in normoxic and
ischaemic mouse hearts,” Cardiovascular Research, vol. 71, no. 1,
pp. 79–87, 2006.
[83] A.Kemeny-Beke,A. Jakab, J. Zsuga et al., “Adenosine deaminase
inhibition enhances the inotropic response mediated by A
1
adenosine receptor in hyperthyroid guinea pig atrium,” Phar-
macological Research, vol. 56, no. 2, pp. 124–131, 2007.
[84] K. Mubagwa, K. Mullane, and W. Flameng, “Role of adenosine
in the heart and circulation,” Cardiovascular Research, vol. 32,
no. 5, pp. 797–813, 1996.
[85] N. Balas, M. Arad, B. Rabinowitz, and A. Shainberg, “Mod-
ulation of cardiac A
1
-adenosine receptors in rats following
treatment with agents affecting heart rate,” Molecular and
Cellular Biochemistry, vol. 231, no. 1-2, pp. 107–116, 2002.
[86] A. Solini, S. Cuccato, D. Ferrari et al., “Increased P2X7 receptor
expression and function in thyroid papillary cancer: a new
potential marker of the disease?” Endocrinology, vol. 149, no. 1,
pp. 389–396, 2008.
[87] L.-Q. Gu, F.-Y. Li, L. Zhao et al., “Association of XIAP and P2X7
receptor expression with lymph node metastasis in papillary
thyroid carcinoma,” Endocrine, vol. 38, no. 2, pp. 276–282, 2010.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
